Literature DB >> 15660520

Management of adult idiopathic thrombocytopenic purpura.

Douglas B Cines1, Robert McMillan.   

Abstract

Idiopathic thrombocytopenic purpura (ITP) is a common hematologic disorder manifested by immune-mediated thrombocytopenia. The diagnosis remains one of exclusion, after other thrombocytopenic disorders are ruled out based on history, physical examination, and laboratory evaluation. The goal of treatment is to raise the platelet count into a hemostatically safe range. The disorder is usually chronic, although there is considerable variation in the clinical course and most patients eventually attain safe platelet counts off treatment. However, a subset of patients has severe disease refractory to all treatment modalities, which is associated with considerable morbidity and mortality. This article focuses on the management of primary ITP in adults. We discuss criteria for treatment, the roles of splenectomy and other treatment options along with their side effects, and the management of ITP during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660520     DOI: 10.1146/annurev.med.56.082103.104644

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  16 in total

1.  Direct B-cell stimulation by peripheral blood monocyte-derived dendritic cells in idiopathic thrombocytopenic purpura patients.

Authors:  Zhenhai Zhou; Xiaoyin Li; Juan Li; Chang Su; Lan Zhuang; Shaokai Luo; Ling Zhang
Journal:  J Clin Immunol       Date:  2010-07-14       Impact factor: 8.317

2.  Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years.

Authors:  Nicola Vianelli; Francesca Palandri; Nicola Polverelli; Roberto Stasi; Joel Joelsson; Eva Johansson; Marco Ruggeri; Francesco Zaja; Silvia Cantoni; Angelo Emanuele Catucci; Anna Candoni; Enrica Morra; Magnus Björkholm; Michele Baccarani; Francesco Rodeghiero
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

3.  Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells.

Authors:  Baijun Fang; Ling Mai; Ning Li; Yongping Song
Journal:  Stem Cells Dev       Date:  2011-08-12       Impact factor: 3.272

Review 4.  Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in women with bleeding disorders and carriers.

Authors:  Laxminarayan Karanth; Adinegara Bl Abas
Journal:  Cochrane Database Syst Rev       Date:  2021-12-09

Review 5.  Immune thrombocytopenia in pregnancy.

Authors:  Evi Stavrou; Keith R McCrae
Journal:  Hematol Oncol Clin North Am       Date:  2009-12       Impact factor: 3.722

6.  Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura.

Authors:  Chengshan Guo; Xiaoxia Chu; Yan Shi; Weidong He; Lizhen Li; Lin Wang; Yingxue Wang; Jun Peng; Ming Hou
Journal:  J Clin Immunol       Date:  2007-07-06       Impact factor: 8.317

7.  A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.

Authors:  Yukari Shirasugi; Kiyoshi Ando; Satoshi Hashino; Toshiro Nagasawa; Yoshiyuki Kurata; Yuji Kishimoto; Koji Iwato; Tomoko Ohtsu; Dietmar P Berger
Journal:  Int J Hematol       Date:  2009-06-20       Impact factor: 2.490

Review 8.  Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in women with bleeding disorders and carriers.

Authors:  Laxminarayan Karanth; Sachchithanantham Kanagasabai; Adinegara Bl Abas
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

9.  Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia.

Authors:  Mohammad Ali Mashhadi; Mahmoud Ali Kaykhaei; Zahra Sepehri; Ebrahim Miri-Moghaddam
Journal:  Daru       Date:  2012-08-28       Impact factor: 3.117

10.  Idiopathic thrombocytopenic purpura.

Authors:  L Kayal; S Jayachandran; Khushboo Singh
Journal:  Contemp Clin Dent       Date:  2014-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.